An interventional study of Dexamethasone and Midazolam injection in Pain Syndrome, sponsored by Minia University. Completed at 1 site in Egypt. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by Minia University · Not applicable, Interventional, and Treatment
midazolam and dexamethasone both can counteract chronic pain. either via GABA mimetic action or via anti prostaglandins
Entrapement syndrome - namely median nerve compression in carpal tunnel syndrome - causes chronic pain that can be refractory to medical treatment . Ultrasound guided hydrodissection is an option for alleviating pain . Recurrence is the main side effect of injection. We try in this research to prevent recurrence rate . Midazolam and dexamethasone both are used in chronic pain . Midazolm act by GABA mimetic action while dexamethasone act by decrease interleukin formation
589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.
This study's enrollment of 134 is above the median of 60 across 445 interventional studies indexed under Carpal Tunnel Syndrome.
Browse Carpal Tunnel Syndrome studies →Minia University is the lead sponsor of 356 studies on the registry; 115 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
sonar guided median nerve hydrodissection by bupivacaine 0.5% and dexamethasone
Drug: Dexamethasone
sonar guided median nerve hydrodissection by bupivacaine 0.5% and midazolam
Drug: Midazolam injection
Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
Also known as: midazolam
intracarpal injection of midazolam and bupivacaine 0.5%
comparing efficacy of midazolam against dexmethasone in combination with bupivacaine 0.5%
use of visual analogue score
Time frame: up to 6 months
Subjective pain assesment
BOSTON questionnaire
Time frame: up to 6 months
complications
neurotoxicity, pain recurrence after injection
Time frame: pain recurrence after 6 months, neurotoxicity immediately after injection
Nerve electrophysiology
sensory nerve conduction , distal motor latency.
Time frame: up to 6 months
nerve sonogram
nerve cross sectional area.
Time frame: up to 6 months
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Minia University